Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 390

Another new venture that could be beneficial for diabetic patients in the long term is the establishment of TrialNet. Funded jointly by the Juvenile Diabetes Research Foundation International (JDRF), the NIH, and the American Diabetes Association (ADA), and approved by Congress, TrialNet is an international network of researchers and scientists whose objective is to explore new ways to delay, prevent, and potentially reverse the progression of type 1 diabetes. TrialNet researchers come from 18 clinical centers in Canada, the United Kingdom, Finland, Italy, New Zealand, Germany, and the United States, and more than 150 medical centers and physician offices.